Manulife Singapore has teamed up with AMILI, Southeast Asia’s pioneering gut microbiome insights company, to offer eligible customers an exclusive gut microbiome screening—a groundbreaking initiative for a life insurer in Singapore. The insurer will announce the eligibility criteria and redemption method at a later date.
“As a life insurer, we are uniquely positioned to offer impactful health solutions that empower our customers to live healthier lives. AMILI’s expertise lies in its ability to analyse the gut microbiome, providing detailed insights into the balance of good and bad bacteria. This enables tailored health recommendations and interventions. We are proud to be the first insurer in the market to provide this cutting-edge service to our customers, and this collaboration exemplifies our vision of transforming the customer experience through health innovation.”
Harshal Shah, Chief Marketing Officer, Asia at Manulife
Through this screening, individuals can gain tailored insights into their gut health, enabling informed decisions to enhance overall well-being. By analysing the trillions of ‘good’ and ‘bad’ bacteria in the gut, the screening provides valuable information to boost immunity, support brain health, and optimise dietary and nutritional choices to help prevent lifestyle-related diseases.
With the increasing demand for holistic health solutions, the test includes access to personalised recommendations that address a range of health concerns, from digestive health and immunity to mental well-being and chronic disease management. AMILI’s physicians will provide an explanation of each customer’s report and provide them with their test results.
“Good health begins with gut health’ as the saying goes. We see incredible potential in what the Singapore health minister describes as “predictive preventive care”, to improve lives by personalising health insights based on the gut microbiome and other data. Our collaboration with Manulife is a significant step towards making personalised screening more accessible, and we’re excited to help customers better manage their health through science-backed insights and actionable recommendations.”
Dr. Jeremy Lim, CEO and co-founder of AMILI.
AMILI houses Southeast Asia’s first and only gut microbiome transplant bank and the world’s largest multi-ethnic Asia gut microbiome database.
